Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica

CER3749
2010 Vol.28, N°5
PI 0756, PF 0758
Brief Papers

Free to view
(click on article PDF icon to read the article)

PMID: 20822713 [PubMed]

Received: 01/04/2010
Accepted : 01/06/2010
In Press: 22/10/2010
Published: 22/10/2010

Abstract

OBJECTIVES:
To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice.
METHODS:
Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA.
RESULTS:
No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse.
CONCLUSIONS:
PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giant-cell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.